Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Dasotraline

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sunovion ditches once-rejected ADHD, binge eating program
    Sunovion ditches once-rejected ADHD, binge eating program

    13 May 2020

    // Amirah Al Idrus FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/sunovion-ditches-once-rejected-adhd-binge-eating-program

    Amirah Al Idrus FIERCE BIOTECH
    13 May 2020
    Share Share
    Sunovion Announces Acceptance by the USFDA of the NDA for Dasotraline
    Sunovion Announces Acceptance by the USFDA of the NDA for Dasotraline

    30 Jul 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190730005170/en/Sunovion-Announces-Acceptance-U.S.-FDA-New-Drug/?feedref=JjAwJuNHiystnCoBq_hl-WFAllVCLJFCqzlmaJ8DKHU4plfPZtlGYRDUHCSmgbii6XkLWuQZD-HgGRnjQvCyg3iCfEFIaJW7-otp9V1XQiK2eHTJy3ZqOEt7kKgLu20J

    BUSINESSWIRE
    30 Jul 2019
    Share Share
    FDA rejects Sunovion's ADHD drug dasotraline
    FDA rejects Sunovion's ADHD drug dasotraline

    04 Sep 2018

    // PHARMA FILE

    http://www.pharmafile.com/news/518521/fda-rejects-sunovions-adhd-drug-dasotraline

    PHARMA FILE
    04 Sep 2018
    Share Share
    FDA rejects Sunovion’s ADHD drug
    FDA rejects Sunovion’s ADHD drug

    04 Sep 2018

    // Selina McKee PHARMA TIMES

    http://www.pharmatimes.com/news/fda_rejects_sunovions_adhd_drug_1251093

    Selina McKee PHARMA TIMES
    04 Sep 2018
    Share Share
    FDA Issues a CRL for NDA for Dasotraline for the Treatment of ADHD
    FDA Issues a CRL for NDA for Dasotraline for the Treatment of ADHD

    31 Aug 2018

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20180831005189/en

    BUSINESSWIRE
    31 Aug 2018
    Share Share
    Sunovion Announces FDA Acceptance for Review of NDA for Dasotraline for ADHD
    Sunovion Announces FDA Acceptance for Review of NDA for Dasotraline for ADHD

    13 Nov 2017

    // BUSINESSWIRE

    http://www.businesswire.com/news/home/20171110005467/en/Sunovion-Announces-FDA-Acceptance-Review-New-Drug

    BUSINESSWIRE
    13 Nov 2017
    Share Share